| 30792533 |
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
Heinrich, MC,
Ketzer, J,
Bauer, S,
Zhu, M,
Presnell, A,
Raut, CP,
George, S,
Mannan, AM,
Serrano, C,
Yu, C,
Sicinska, E,
Tao, DL,
Rubin, BP,
Fletcher, JA,
Mariño-Enríquez, A,
Demetri, GD,
Eilers, G,
Czaplinski, JT,
McKinley, A
|
Br. J. Cancer |
2019 |
| 16397263 |
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies
Shiraga, S,
Schroeder, A,
Bokemeyer, C,
Deininger, MW,
Heinrich, MC,
Druker, BJ,
Schittenhelm, MM,
Lee, FY,
Corbin, AS,
Griffith, D
|
Cancer Res. |
2006 |
